Featuring a slide presentation and related discussion from Dr Brian Slomovitz, including the following topics:
- Recent data with PARP inhibitors alone and in combination with other agents as maintenance therapy for advanced ovarian cancer; recent data with novel agents (0:00)
- Efficacy data with pembrolizumab/chemotherapy from the KEYNOTE-826 trial; biologic rationale for targeting tissue factor and emerging data with tisotumab vedotin for cervical cancer (16:45)
- PFS2 data (disease progression on next line of therapy after first progression) with lenvatinib/pembrolizumab for advanced endometrial cancer; recent data with dostarlimab and mTOR inhibitors (23:58)
CME information and select publications
Research To Practice | Oncology Videos